Highest-materiality recent filing
Biohaven licenses opakalim/Kv7 platform to SK Biopharmaceuticals for up to $795M
SK Biopharmaceuticals licenses Biohaven's Kv7 platform led by opakalim, a Phase 2/3 selective Kv7.2/7.3 activator for focal epilepsy.
Biohaven Q2 net loss narrows to $137.3M; advances Graves, epilepsy, oncology pipeline
Net loss $137.3M ($0.91/share) vs $198.1M ($1.94/share) in Q2 2025; non-GAAP loss $118.1M ($0.78/share).
Opakalim 75 mg prolonged median time to second seizure to 141 days vs 47 days for placebo in idiopathic generalized epilepsy trial.
Biohaven establishes $350M at-the-market equity offering via amended agreement with J.P. Morgan
Amendment No. 2 to Equity Distribution Agreement allows up to $350M in common share sales.
Biohaven Q1 net loss $130.5M; pivotal epilepsy & obesity data due 2H 2026
Net loss $130.5M ($0.88/sh) vs $221.7M ($2.17/sh) in Q1 2025; non-GAAP adjusted loss $102.2M ($0.69/sh).
Biohaven reports Q4 loss $145.6M, prioritizes three late-stage programs, raises $178.9M
Q4 net loss $145.6M ($1.21/sh); non-GAAP adj. net loss $107.9M ($0.90/sh).
Biohaven to issue 12.5M shares at $10 each to Janus Henderson, raising $125M gross
12,500,000 common shares at $10.00 per share, $125M gross proceeds expected.
Biohaven closes $200M public offering of 26.8M shares at $7.50/share
Gross proceeds of approximately $200M from 26,833,334 common shares, including full exercise of underwriters' 3.5M share option.
Biohaven reports Q3 net loss $173.4M, plans 60% R&D spend cut to focus on three late-stage programs
Net loss $173.4M ($1.64/share) vs $160.3M ($1.70/share) YoY; non-GAAP loss $155.9M ($1.47/share).
FDA cancels advisory committee meeting for Biohaven's troriluzole NDA; decision still Q4 2025
FDA informed Biohaven on Aug 21, 2025 that an advisory committee meeting is no longer needed for troriluzole NDA review.
Biohaven amends Knopp deal: royalty cut to mid-single digits, milestones reduced by >$800M
Removed up to $562.5M in commercial sales milestones; reduced developmental/regulatory milestones from $575M to up to $210M.
Biohaven reports Q2 net loss $198M, cash $408.2M; OCD trial fails, VYGLXIA PDUFA in Q4 2025
Net loss of $198.1M ($1.94 per share) vs $319.8M in Q2 2024; no revenue, clinical-stage biopharma.
FDA extends Biohaven's troriluzole PDUFA date to 4Q 2025, plans advisory committee meeting
FDA extends PDUFA date by 3 months to 4Q 2025 for troriluzole NDA for spinocerebellar ataxia (SCA).
Biohaven Q1 net loss $221.7M; announces $600M Oberland capital deal for troriluzole launch
Net loss of $221.7M ($2.17 per share); non-GAAP adjusted net loss $166.8M ($1.64 per share).
First tranche $250M funded at closing on or before April 30, 2025.
Biohaven reports $489M cash; FDA accepts troriluzole NDA with Priority Review for SCA
Cash & securities totaled $489M as of Dec 31, 2024; R&D expenses Q4 2024 were $167.5M (vs $134.8M Q4 2023).
Biohaven reports Q3 net loss $160.3M; troriluzole SCA trial positive, NDA submission planned Q4 2024
Net loss $160.3M ($1.70/sh) vs $102.6M loss ($1.50/sh) in Q3 2023; non-GAAP adj. net loss $164.1M ($1.74/sh).
Biohaven completes $287.5M equity offering; 6.05M shares at $47.50
Sold 6,052,631 common shares including full underwriter option at $47.50/share.
Biohaven troriluzole pivotal SCA study meets primary endpoint; NDA planned Q4 2024
Troriluzole 200 mg once-daily met primary endpoint on f-SARA change from baseline at 3 years in all SCA genotypes.
Biohaven expands at-the-market equity facility by $300M to total potential issuance
Amendment No. 1 increases existing ATM capacity by $300M in common shares; sales via J.P. Morgan as manager.
Biohaven Q2 net loss $3.64/sh; pipeline highlights MoDE degrader data and FDA alignment for BHV-8000
Net loss of $319.8M ($3.64/sh) in Q2 2024 vs $1.32/sh in Q2 2023; cash ~$440M.
Net loss $179.5M ($2.20/shr); non-GAAP adjusted net loss $144.6M ($1.77/shr); both more than doubled vs Q1 2023.
Biohaven completes $264.5M public offering of common shares at $41.00 per share
Issued and sold 6,451,220 common shares at $41.00/share, including full exercise of underwriters' option.
Biohaven presents BHV-1300 Ph1 SAD data: safe, dose-dependent IgG lowering in 16 subjects
16 subjects completed two dosing cohorts; no SAEs, only mild AEs unrelated to drug.
Biohaven Q3 net loss $102.6M ($1.50/share); cash $495M after public offering; pipeline advances
Net loss of $102.6M ($1.50/share) vs $68.9M ($1.75/share) in Q3 2022; non-GAAP adjusted net loss $98.1M ($1.44/share).
Biohaven raises ~$258.7M in public offering of 11.8M shares at $22.00/share
Issued 11,761,363 common shares including full underwriter option at $22.00 per share.
Biohaven reports >90% IgG reduction with BHV-1300 bispecific degrader after repeat dosing
BHV-1300 bispecific IgG degrader achieved >90% reduction in IgG after repeat dosing in pharmacodynamic study.
Biohaven Q2 net loss $90.3M; cash $349M; FDA refuses SCA3 NDA; pipeline advances
Net loss $90.3M ($1.32/sh) vs $203.3M ($5.16/sh) in Q2 2022; adjusted net loss $85.7M ($1.25/sh).
FDA refuses troriluzole NDA for SCA; BHV-7000 EEG data positive
FDA refused to file troriluzole NDA for SCA because primary endpoint not met; company may request Type A meeting within 30 days.
Biohaven submits NDA for troriluzole in SCA3; updates on Kv7, TYK2/JAK1, and SMA pipeline
Submitted NDA to FDA for troriluzole in SCA3, an ultra-rare disease affecting ~10,600 people in NA, EU, Japan.
Biohaven Q1 net loss $70.5M; cash $392M; pipeline progress, TYK2/JAK1 license acquired
Net loss of $70.5M ($1.03/share); non-GAAP adjusted net loss $66.7M ($0.98/share).
Biohaven Q4 2022 net loss $201.1M; licenses TYK2/JAK1 inhibitor BHV-8000
Q4 2022 net loss $201.1M ($3.32/share); cash $465.3M at year-end, no debt.
Biohaven posts Q3 net loss $68.9M; launches post-Pfizer with $257.8M cash, raises $301.9M offering
Net loss of $68.9M ($1.75/share) vs $54.4M loss in Q3 2021; non-GAAP adjusted loss $49.2M ($1.25/share).
Designated as Class II directors, with initial terms expiring at the 2024 annual meeting of Biohaven shareholders: • Gregory Bailey • John Childs
Designated as Class II directors, with initial terms expiring at the 2024 annual meeting of Biohaven shareholders: • Gregory Bailey
Designated as Class III directors, with initial terms expiring at the 2025 annual meeting of Biohaven shareholders: • Vladimir Coric • Kishan Mehta
On September 28, 2022, the Company appointed Matthew Buten as Chief Financial Officer.
Designated as Class III directors, with initial terms expiring at the 2025 annual meeting of Biohaven shareholders: • Vladimir Coric • Kishan Mehta
Designated as Class I directors, with initial terms expiring at the 2023 annual meeting of Biohaven shareholders: • Irina Antonijevic • Michael T. Heffernan • Robert Hugin
Designated as Class I directors, with initial terms expiring at the 2023 annual meeting of Biohaven shareholders: • Irina Antonijevic • Michael T. Heffernan
Designated as Class II directors, with initial terms expiring at the 2024 annual meeting of Biohaven shareholders: • Gregory Bailey • John Childs • Julia Gregory
The following persons were appointed as directors of Biohaven on September 28, 2022: Designated as Class I directors, with initial terms expiring at the 2023 annual meeting of Biohaven shareholders: • Irina Antonijevic
Max materiality 0.95 · Median 0.70 · Most common event other_material